CCS Healthcare has entered into an agreement with Merck Sharp & Dohme (Sweden) to acquire the pharmaceutical skin care product and trademark Propyless.
Propyless is a lotion, based on active substance propylene glycol, used for dry skin, atopic dermatitis and psoriasis. Introduced in the late 1980s it is a well-known registered trademark in the Swedish market.
“Propyless is a leading product in its niche on the Swedish market and fits well with our targeted growth strategy. It complements well our current pharmaceutical and skin care offering,” says Jonas Nilsson, CEO of CCS Healthcare.
With sales of approximately SEK500m and headquartered in Borlänge, Sweden, CCS Healthcare is a Nordic manufacturer and distributor of personal care and healthcare products, focused on skin care, pharmaceuticals and dental products. CCS Healthcare is market leader in disinfection in Sweden and Norway with its Dax and Antibac brands.
